anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To provide a soft capsule comprising an edible capsule coating film not containing an animal protein and capable of being easily dissolved, high in safety, and used for medicines and foods. CONSTITUTION:Three kinds of components comprising an edible polymeric substance (e.g. alginic acid) which can easily be dissolved in water, whose 1% aqueous solution has a viscosity of &lt;=1000 cps at 70 deg.C, and which does not contain an animal protein as a film-forming base agent, an agar and/or a low mol. wt. agar having a jelly strength of &lt;=300g/cm&lt;2&gt; a gelled filmforming base agent, and a plasticizer (e.g. glycerol) are-combined with each other to provide a soft capsule coating film-forming material. The soft capsule coating film-forming material is prepared into a soft capsule by a dropping method. By the method, a capsule content solution and the capsule coating film-forming material solution are extruded from an inside extrusion nozzle and an outside extrusion nozzle, respectively, among the nozzles of a triple or double structure into an oily liquid at a constant rate with a pump or the gravity, and the extruded solution is cut at a constant distance by some physical force such as vibration, impact or the difference between the flow rates of the capsule solution and the oily liquid, thus forming spherical soft capsules each having a diameter of 0.3-20mm by the interfacial tension between the oily liquid and the capsule coating film-forming solution.
Methods and apparatus are provided for increasing and/or monitoring a party&#39;s compliance with a schedule for taking medicines. In a first embodiment, a method is provided for use by a first container that is adapted to store a first medicine. The method includes storing information regarding the first medicine and wirelessly communicating a signal between the first container and a second container adapted to store a second medicine. In a second embodiment, a method is provided that includes determining if a first container for storing a first medicine is positioned so as to wirelessly communicate with a second container for storing a second medicine. The method further includes generating data based at least in part on whether the first container is positioned so as to wirelessly communicate with the second container. In a third embodiment, a method is provided that includes receiving a signal and, based at least in part on the received signal, determining whether a first container for storing a first medicine was positioned so as to wirelessly communicate with a second container for storing a second medicine. In a fourth embodiment, a method is provided that includes receiving a signal from a device that monitors whether a first container for storing a first medicine and a second container for storing a second medicine are positioned so as to communicate. The method further includes determining if at least one party has complied with a schedule for taking the first medicine and the second medicine based at least in part on the received signal. Systems, apparatus and computer program products are provided for carrying out the above-described embodiments and numerous other embodiments.
The invention discloses a kind of Viburnum opulus Linn. var. calvescens (Rehd.) Hara f. calvescens branches and leaves lignanoid and extracting method and purposes, dry Viburnum opulus Linn. var. calvescens (Rehd.) Hara f. calvescens branches and leaves are crushed etc.；Using thermostatic ultrasonic instrument warm water suspension medicinal extract, extraction, reduced pressure, medicinal extract is obtained；Chloroform extract medicinal extract methanol is taken to dissolve, elution removes chlorophyll, is chromatographed, is purified, and different compounds in 5 are obtained.The monomer lignanoid purity that the present invention obtains reaches 96%~99%, can carry out Objective structural modification, is applied to pharmaceutical synthesis, obtains the better drug molecule of activity；5 lignanoids are to extract from Viburnum opulus Linn. var. calvescens (Rehd.) Hara f. calvescens for the first time, so that the approach for obtaining this kind of active skull cap components is more extensive.Simple and convenient extraction of the present invention, the easily separated recycling of organic solvent combination, blowdown is few, is suitable for modern fine industrial production.The present invention uses newest SBC MCI GEL reverse-phase chromatography filler, and the removal rate of chlorophyll is made to be increased to 97%~100% from 60%~70%.Present invention discloses the antiatherosclerosis purposes of lignanoid&#39;s monomer.
An advanced biometric bracelet has been designed that can monitor vital signs in emergencies and critical situations. Thanks to facial recognition technology, this bracelet records, displays, and sends the patient&#39;s data to the doctor. In situations where the number of patients or clients to hospitals and medical centers is high, or in case of natural disasters, this bracelet can alleviate probable risks by shortening the waiting time of patients. Equipped with biometric sensors, this bracelet can record vital signs including blood oxygen level, heart rate, and body temperature. In emergencies, the bracelet will alert and store the data for a while so that the doctor can check for fluctuations. The camera mounted on the bracelet helps to save the changes in the patient&#39;s face in the memory of the device and transmit it to the doctor via Wi-Fi.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide foods and beverages exhibiting antithrombotic effect in antithrombotic foods and beverages effectively utilizing distillation residue which is a waste product for production of Shochu (Japanese distilled spirit).  &lt;P&gt;SOLUTION: The antithrombotic food and beverage comprise a distillation residue, obtained as a by-product of Shochu produced by a conventional method by using barley, rye, naked barley, adlay, etc., as a raw material, in which the majority of the residue is treated as an industrial waste, particularly a distillation residue of Shochu using barley as a raw material as an active ingredient. The antithrombotic food and beverage are obtained by adding the distillation residue to various kinds of foods and beverages. The distillation residue is formed in powder, tablet, capsule, etc., to provide a health food or the distillation residue is added to various kinds of beverages, e.g. an alcoholic beverage such as Shochu or a fruit-containing beverage, isotonic beverage, etc. to provide the antithrombotic food and beverage.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject dispersion having improved bioavailability and stability and useful as a composition for oral administration by including cefuroxime axetile, a surfactant and a water-insoluble inorganic substance carrier. SOLUTION: This dispersion is obtained by including (A) cefuroxime axetile, (B) a surfactant which is preferably a polyoxyethylene-polyoxypropylene block copolymer or the like and (C) a water-insoluble inorganic substance carrier which is preferably silicon dioxide. The amounts of the contained ingredients based on 100 pts.wt. of the ingredient A are preferably 1-50 pts.wt. of the ingredient B and 1-200 pts.wt. of the ingredient C. Furthermore, a water-insoluble additive such as a microcrystalline cellulose in an amount of &lt;=100 pts.wt. based on 100 pts.wt. of the ingredient A is preferably contained in the dispersion.
FIELD: hygiene. SUBSTANCE: the present innovation deals with manufacturing products of personal hygiene. The suggested detergent contains foundation as milk substitute&#39;s whey as &#34;soybean milk&#34; with milk whey, alkylsulfates, dyestuff, scent, conservant, mineral salts, pearly additive and pH value regulator. Method to prepare the suggested detergent includes preliminary purification due to filtration or centrifuging the foundation as the whey of &#34;soybean milk&#34; milk substitute from artefacts and coagulated protein by heating up to 60-100 C followed by cooling and adding the rest components at constant mixing process. EFFECT: higher efficiency. 6 cl, 1 tbl
FIELD: medicine. ^ SUBSTANCE: invention concerns experimental biology. The method involves taking a vegetable drug. The vegetable drug is a phytococktail which contains snowdone rose, eleuterococcus, common licorice and elfwort in the form of 70% alchoholates which are taken in the proportion 2:2:1:1 and dissolved in distilled water in the proportion 1:50. Phytococtails are taken through a probe of 1 ml according to animals chronotype within 16.00 to 18.00 o&#39;clock for 15 days. ^ EFFECT: method allows improving peripheral microcirculation in healthy animals in experiment as well as reducing a risk of clinical and experimental cardiovascular complications. ^ 1 tbl
The invention relates to a novel therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine). Acadesine (also known as AICA riboside or AICAR) does not inhibit apoptosis in lymphocytes, as would be expected, but it does induce apoptosis in the B-cells of patients with B-type lymphoproliferative diseases, such as chronic B-cell (B-CLL) lymphatic leukaemia, splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL) and Waldenstrom&#39;s syndrome (WS). The T-cells are not affected. As a result, acadesine and the bioprecursors thereof (e.g. the mono, di- and tri-5&#39;-phosphates thereof) are converted into therapeutic agents that can be used against lymphoproliferative diseases in humans. The surprising characteristic whereby the T-cells are barely affected means that the adverse secondary effect (immunosuppression) is slight, which represents a therapeutic advantage offered by acadesine over cladribine, fludarabine and other nucleosides known in the art.
In a process for obtg. sperm enriched with andro- or gymnosperms in amts. sufficient for insemination purposes in which the sperm fromone ejaculate is contacted with a tract of a spermatozoa motility stimulant and after a prolonged contact time the tract is divided into two parts, the part nearest the start point having an increased gymnosperm content and the part remote from the start point having an increased androsperm content, the sperm is divided among several tracks simultaneously and the motility stimulant is formulated as a cryobiologically active protective colloid by adding suitable additives. Immediately after the sepn. of each of the several tracks into 2 parts, each part is frozen. Further ejaculates from the same donor are subjected to the same procedure until the collected andro- or gymnosperms contain at least 30-60 x 106 sperms/cm3 (i.e. the amt. required for an acceptable insemination success rate). Immediately before insemination, the collected androsperm or gymnosperm-enriched material is thawed, pooled, and opt. concd. by removing as far as possible the carrier consisting of motility-increasing material and protective colloid. The procedure makes effective use of the finding that androsperms have greater motility than gymnosperms in order to give sperm enriched in either of the two sex determinants. This permits an infant&#39;s sex to be predetermined at the time of insemination, which can be desirable on social or (in the case of animals) economic grounds. In addition, the procedure permits the accumulation of an effective amount of sperm in the case of prospective fathers who are infertile due to low sperm counts.
Abstract Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation there-of, and pharmaceutical compositions containing them.            Disclosed are novel derivatives of polyene macrolide antibiotics of the general formula       (I) wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is (II),   (III), -R5 or hydrogen, wherein A and B independently of each other are hydrogen or NR3R4 or one of A and B is hydrogen and the other is -NH-?-R-NR3R4, R5 is an .alpha.-amino-acyl group; n is 1 to 3, t is zero or 1, and when t is zero p is zero to 4 and when t is 1 p is zero; z is zero or 1, and Y is hydrogen,    alkyl, allyl, propargyl, benzyl or phenylpropargyl, with the proviso that, when X is hydrogen, z must be 1 and Y allyl, propargyl, benzyl or phenylpropargyl; and the pharmaceutically acceptable acid addition salts thereof.            The novel compounds may be prepared by methods known per se.  Preferably the compounds are prepared by reaction of respective polyene macrolide antibiotic with a reactive derivative of a compound HOX&#39; wherein the amino group(s) is(are) protected.  The compounds wherein X is hydrogen and Y is allyl, propargyl, benzyl or phenylpropargyl can be prepared by reaction of the respective N-protected polyene macrolide antibiotic with  a  reactive derivative of propene, propyne, phenylpropyne or toluene.            The compounds show antifungal activity and are useful in the treatment of fungal infections.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for inhibiting aberrant splicing of a pre-mRNA molecule by using an antisense oligonucleotide, to develop a method for upregulating gene expression and to provide the antisense oligonucleotide useful for performing the method.  &lt;P&gt;SOLUTION: The method for inhibiting aberrant splicing of the pre-mRNA including a mutation is disclosed. The antisense oligonucleotide is hybridized to the pre-mRNA molecule to create a duplex molecule under a condition which permits splicing. The antisense oligonucleotide does not activate ribonuclease H, and is selected to block a constituent element of the aberrant set of splice elements created by the mutation, thus, the native intron is removed by the splicing and the first mRNA molecule encoding a native protein is produced. Oligonucleotides useful for performing the method are also provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The invention provides a novel antibiotic of Gram-positive bacteria and also provides a strain Streptomycesspectabilis zgd-Q for producing the novel antibiotic. The strain Streptomycesspectabilis zgd-Q is preserved in the China center for type culture collection On September 13, 2012 and has a preservation number of CCTCC No. M2012328. The strain Streptomycesspectabilis zgd-Q having the preservation number of CCTCC No. M2012328 is cultured and an extract is separated from a fermentation broth and then is purified to form the novel antibiotic. The novel antibiotic has a molecular formula of C39H49NO14, has molecular weight of 755 and [M+K]&lt;+&gt; of 794, has a chemical name of 17-carbonyl-19-methoxy-streptovaricin F, can act on Gram-positive bacteria, has a phenol coefficient of 2.0 to 12.8, and has strong effects of killing Gram-positive bacteria.
The present invention relates generally to novel molecules capable of, inter alia, modulating apoptosis in mammalian cells and to genetic sequences encoding same. More particularly, the present invention relates to a novel member of the Bcl-2 family of proteins, referred to herein as &#34;Bmf&#34;, and to genetic sequences encoding same and to regulatory sequences such as a promoter sequence directing expression of Bmf. Bmf comprises a BH3 domain which facilitates interaction to pro-survival Bcl-2 family members thereby triggering apoptosis. Bmf is regarded, therefore, as a BH3-only molecule. The molecules of the present invention are useful, for example, in therapy, diagnosis, antibody generation and as a screening tool for therapeutic agents capable of modulating physiological cell death or survival and/or modulating cell cycle entry. The present invention further contemplates genetically modified animals in which one or both alleles of Bmf are mutated or partially or wholly deleted alone or in combination with a mutation in one or both alleles of another Bcl-2-type molecule such as but not limited to Bim. The genetically modified animals are useful inter alia in screening for agents which ameliorate the symptoms of diseases caused by defects in apoptosis or which specifically promote apoptosis of target cells.
Methods of immunizing individuals against prostate cancer are disclosed. Methods of protecting an individual against prostate cancer and methods of treating individuals who have prostate cancer are also disclosed. Methods of inducing a cellular immune response against prostate specific antigen are also disclosed. In the disclosed methods, a nucleic acid molecule that comprises a nucleotide sequence that encodes prostate specific antigen or an immunologically active fragment thereof is administered to a site on an individual&#39;s body. The nucleotide sequence is operably linked to regulatory sequences which control the expression of the nucleotide sequence in cells of the individual. Pharmaceutical compositions are also disclosed. Methods for assessing the effectiveness of a prostate cancer vaccine to induce an immune response against prostate specific antigen in an individual, and kits for performing the same are also disclosed.
PURPOSE: To efficiently obtain spiro [isoquinoline-4(1H), 3&#39;pyrrolidine]1,2&#39;,3,5&#39;(2H) tetrone useful as an aldose reductase inhibitor, etc., by allowing 2-bromobenzoic acid, etc., as starting material to react with dimethyl malonate, etc.  
     CONSTITUTION: A compd. of formula I (where R 1  is H or a halogen) is allowed to react with dimethyl malonate and sodium hydride in the presence of a catalytic amt. of copper bromide to form a compd. of formula II. This compd. is allowed to react with thionyl chloride and treated with a compd. of the formula R 2 NH 2  (where R 2  is a dihalogen substd. benzyl or methyl) in an ordinary solvent in the presence of triethylamine to form a compd. of formula III. This compd. is allowed to react with bromoacetonitrile in an ordinary solvent in the presence of potassium carbonate to form a compd. of formula IV. This compd. is allowed to react with gaseous HCl in methanol and diethyl ether and the resultant compd. of formula V is allowed to react with a base in an ordinary solvent to obtain the objective compd. of formula VI. 
     COPYRIGHT: (C)1993,JPO
1416564 Treating human hair WELLA AG 14 March 1973 [21 March 1972] 12328/73 Heading D1P Human hair is permanently deformed by allowing a forming agent containing a water soluble mercapto carboxylic acid salt and a salt of glyoxylic acid to act on the hair, after which the hair is fixed by treatment with a fixing agent containing hydrogen peroxide or a compound of addition thereof, and without intermediate rinsing of the hair. &#39;The mercapto carboxylic acid salt used is preferably a water-soluble salt of thioglycolic acid or thiolactic acid. A salt of ascorbic acid may be added to the glyoxylic acid salt. The salts of glyoxylic acid and optionally ascorbic acid may be present in a total concentration of from 2 to 4% by weight based on the total weight of the agent. For the permanent waving of hair, the hair may be first moistened with a part of the forming agent and then wound on to permanent waving curlers, further moistened with the remainder of the forming agent and optionally covered with a hood-like plastic cloth. After an action time of 10-20 minutes, the curled hair is thoroughly moistened with part of the fixing agent which is left to act for 2-3 minutes. Then, after removing the hair from the curlers the remaining fixing agent is applied and left to act for a further one to three minutes. Finally the hair is rinsed with water and after-treated to produce the hair style. Permanent straightening of crinkly hair may be effected by applying the forming agent in a thickened formulation and allowing it to act for 10-20 minutes while combing the hair repeatedly. The hair is then treated for 3-7 minutes with a thickened formulation of the fixing agent, after which the hair is rinsed in water and after-treated to produce the hair style. Forming and fixing agents are exemplified which, on admixture, produce a temperature rise of up to 50C. Further heat may be supplied during the initial treatment of the hair e.g. by a hair dryer.
PROBLEM TO BE SOLVED: To obtain the subject injection capable of eliminating an operation of dissolving with an electrolyte solution or a sugar liquid, avoiding pollution on preparing a medicine and preventing ogzarel sodium from decomposition by filling an ozgarel sodium solution consisting of ogzarel sodium and an aqueous solvent in a hermetically sealed container. SOLUTION: This objective injection is obtained by filling an ogzarel sodium solution consisting of 1 pt.wt. ogzarel sodium and 5-5,000 pt.wt. aqueous solvent (preferably a distilled water or saline for injection) into a hermetically sealed container preferably not transmitting essentially &lt;=350 nm ultraviolet light (preferably a brown colored ampoule). It is possible to add an additive such as a stabilizer, buffering agent, etc., to the ogzarel solution (content liquid). The amount of the ogzarel sodium is preferably 10-100 mg per one container, and the amount of the content liquid is preferably 1-10 ml. The injection can be used by adding into an electrolyte liquid or a sugar liquid and by continuous intravenous injection.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop a material and a related method for manufacturing an intraluminal stent for providing a designer of a device with an opportunity to design the device for a specific application by engineering technologies.  &lt;P&gt;SOLUTION: A biocompatible material can be designed as various kinds of medical devices which can be implanted, including the intraluminal stent. All the devices including the stent can be manufactured using polymeric materials. The stent can be balloon-expansible or self-expansible. Some desired performance characteristics can be obtained by selectively and mechanically deforming polymers and orienting polymer chains.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an artificial pumice filled with a metabolism accelerator such as salt, an antibacterial agent or a perfume.  &lt;P&gt;SOLUTION: By mixing a microencapsulated perfume 1 into a hard synthetic resin foam 10 such as a polyurethane, the releasing effect of the metabolism accelerator or the perfume can be expected. Furthermore, even if the perfume is volatile, since the microcapsule does not release a scent until it gets broken, the perfume is very sustainable. A salt or other metabolism accelerator 2 may be added when required. Such an artificial pumice has also aromatic, perspiratory and antibacterial functions in addition to a keratin removal function.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Compositions which deliver adsorbents, alone or in combination with active drug &#39;degrading molecules,&#39; in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, are disclosed. Methods of treatment using the compositions are also disclosed. The material to be eliminated can include residual active antibiotics, metabolites, bacterial or other toxins, and drugs which cause side effects in the gastrointestinal tract. The adsorbents can be formulated in capsules, tablets or any acceptable pharmaceutical composition, and are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. The programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon.